- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01180244
The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is increasing acceptance that pain in fibromyalgia is a result of dysfunctional sensory processing in the spinal cord and brain. Electrical cortical stimulation is a device-based form of therapy that is increasingly being considered as an adjuvant to current medical modalities for the treatment of chronic pain conditions such as fibromyalgia. The investigators propose that stimulation of cortical areas believed to be involved in dysfunctional sensory processing may have a beneficial influence on fibromyalgia symptoms.
The aim of this randomized double blind, placebo controlled study is to evaluate the efficacy, safety, and tolerability of noninvasive cortical stimulation in the management of fibromyalgia symptoms. More specifically, an active treatment group of subjects will receive the study's cortical stimulation protocol twice a week for 11 weeks and will be evaluated within 14 days following end of treatment, for a total timeframe of 13 weeks. In comparison, a similar group of subjects will receive the same treatment protocol without the actual stimulation signal being applied. The signal utilized is a modulated form that permits very low-intensity signals to pass through outer tissues with less attenuation due to tissue impedance. The signals are of a sufficiently low strength that they are below the level of perception. Hence subjects cannot feel the signal, and are therefore blinded to treatment arm. Investigators and clinical staff are also blinded. Outcome measures include post-treatment to baseline changes in tender points, sleep characteristics as measured by visual analog scales, and outcomes instruments including the Fibromyalgia Impact Questionnaire.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Flint, Michigan, United States, 48532
- McLaren Regional Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 through 65 years
- An ability to read and comprehend English
- Completion of a minimum of grade 8 education
- Diagnosis of fibromyalgia in 1999 or earlier, by a rheumatologist or appropriate specialist, and currently meeting the American College of Rheumatology 1990 criteria
- Symptoms for at least 48 months with no recent remission of symptoms to any degree
Exclusion Criteria:
- Developmental disabilities, or significant psychological disorder (except depression and anxiety disorders) for which treatment has become necessary
- A history of chronic infection or chronic condition such as lupus, rheumatoid arthritis, Parkinson's Disease, multiple sclerosis, hepatitis, history of meningo-encephalitis, polio, seizures, or metastatic cancer
- Current pregnancy, or plans to become pregnant during the study period.
- Any other condition deemed to pose a risk to the patient at the discretion of the investigators
- Exposure to other neurostimulation systems, or electroconvulsive therapy
- Any implantable electronic device
- Any present or previous litigation regarding their physical condition
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active treatment
Subjects in this group will receive the noninvasive cortical stimulation signal from the treatment device
|
Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks.
The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz.
Exact protocol is set in software and is the same for all participants in the active treatment arm.
Other Names:
|
Placebo Comparator: Placebo group
Subjects in this group will be provided the same experience as those in the active treatment arm, but will not receive the noninvasive cortical stimulation signal from the treatment device
|
Subjects in the placebo group will receive the exact same experience as those in the active treatment group.
However, the device will not output any electrical stimulation signal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Tender Point Pain Threshold
Time Frame: Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
Tender point pain threshold is derived by summing the dolorimetry-based pain pressure thresholds measured on a subject for each of the 18 tender points sites specified by the American College of Rheumatology for fibromyalgia classification.
The range of dolorimeter values for each tender point site is 0-4 (units are kilograms per square centimeter, i.e. kg/cm^2).
Higher numbers represent greater pressure required to elicit pain, and are thus indicators of "less pain" sensitivity at the tender point.
Since 18 tender points are measured on a patient and their individual dolorimeter values summed, the range of tender point pain threshold values is 0-72.
A higher score represents less overall pain sensitivity.
The change in tender point pain threshold is determined by subtracting values at baseline from values at end of treatment.
Thus a positive difference represents pain improvement (i.e.. a better outcome).
A negative difference represents pain worsening (i.e. a worse outcome).
|
Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Number of Positive Tender Points
Time Frame: Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
The number of positive tender points ranges from 0-18, and are defined per criteria set forth by the American College of Rheumatology and based on dolorimetry measurements made on 18 prescribed tender point locations.
A tender point is considered "positive" if less than 4 kilograms per centimeter squared pressure is required to elicit a painful response.
The change in number of positive tender points is determined by subtracting the number of positive tender points at baseline from the number of positive tender points at end of treatment.
Thus, a negative number represents pain improvement (i.e.
better outcome), whereas a positive number represents a worsening of pain (i.e.
worse outcome).
|
Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
Change in Fibromyalgia Impact Questionnaire Overall Score
Time Frame: Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
The Fibromyalgia Impact Questionnaire yields a score ranging from 0 to 100, with higher scores representing a greater impact or level of symptoms.
The change in Fibromyalgia Impact Questionnaire is determined by subtracting scores at baseline from scores at end of treatment.
Thus negative numbers represent symptom improvement (i.e. a better outcome) and positive numbers represent symptom worsening (i.e. a worse outcome).
|
Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
Change in Fibromyalgia Impact Questionnaire Pain Visual Analog Scale
Time Frame: Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
The Fibromyalgia Impact Questionnaire includes a pain visual analog scale (VAS) with ranges of 0-10 centimeters.
Higher values represent greater pain.
The change in Fibromyalgia Impact Questionnaire pain visual analog scale is determined by subtracting baseline VAS values from end of treatment VAS values.
Thus, a negative value represents pain improvement (i.e. a better outcome), while a positive value represents pain worsening (i.e. a worse outcome).
|
Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
Change in Fibromyalgia Impact Questionnaire Sleep Satisfaction Visual Analog Scale
Time Frame: Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
The Fibromyalgia Impact Questionnaire includes a sleep visual analog scale (VAS) with ranges of 0-10 centimeters.
Higher values represent greater difficulty with sleep.
The change in Fibromyalgia Impact Questionnaire sleep visual analog scale is determined by subtracting baseline VAS values from end of treatment VAS values.
Thus, a negative value represents sleep improvement (i.e. a better outcome), while a positive value represents sleep worsening (i.e. a worse outcome).
|
Total timeframe 13 weeks: baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeffrey B Hargrove, PhD, Kettering University
- Principal Investigator: Susan J Smith, MD, McLaren Regional Medical Center
- Principal Investigator: Sunil Nagpal, MD, McLaren Regional Medical Center
- Principal Investigator: David G Simons, MD, Emory University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Yousra Hisham Abdel FattahCompletedFibromyalgia, PrimaryEgypt
-
Forest LaboratoriesCypress Bioscience, Inc.TerminatedPrimary FibromyalgiaUnited States
-
Universidade Federal do Rio Grande do NorteCompleted
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
University of ManitobaCompleted
Clinical Trials on Noninvasive cortical electrical stimulation
-
Northstar NeuroscienceCompletedStroke | Broca's AphasiaUnited States
-
Hospices Civils de LyonUnknown
-
University of ArkansasStanford UniversityCompleted
-
MetroHealth Medical CenterThe Craig H. Neilsen FoundationEnrolling by invitation
-
Spanish Foundation for Neurometrics DevelopmentCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); University of HoustonRecruitingBrain Neoplasm | Metastatic Malignant Neoplasm in the Brain | Recurrent Brain NeoplasmUnited States
-
Huashan HospitalShanghai Zhongshan Hospital; Huashan Hospital North, Fudan UniversityNot yet recruiting
-
Chinese University of Hong KongRecruitingHeart FailureHong Kong
-
Medical University of South CarolinaNational Alliance for Research on Schizophrenia and Depression; MedtronicActive, not recruiting